Resources

To health care professionals

Handbook CABOMETYX. Side effect management of CABOMETYX and TKI

Detail Aid. Information about METEOR and CABOSUN trial and how to use CABOMETYX

Reprint – Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial «T Choueiri et al – The Lancet Oncology

Reprint – Cabozantinib versus  sunitinib as initial therapy(CABOSUN) T Choueiri et al – The European Journal of Cancer

To patients

Patient guide + a diary – what you need to know as a patient when you start your treatment

Patient start kit – patient guide + some supportive care for PPE/skin tox.

Resources

© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.se website. This website is intended for Sweden Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

 

I AM A SWEDEN HEALTHCARE PROFESSIONAL

I AM A EU HEALTHCARE PROFESSIONAL

I AM NOT A SWEDEN HEALTHCARE PROFESSIONAL